open access

Vol 48, No 6 (2014)
Review article
Submitted: 2014-10-06
Get Citation

Does interferon beta therapy affect survival of multiple sclerosis patients?

Alina Kułakowska, Wiesław Drozdowski
DOI: 10.1016/j.pjnns.2014.10.003
·
Neurol Neurochir Pol 2014;48(6):436-441.

open access

Vol 48, No 6 (2014)
Review article
Submitted: 2014-10-06

Abstract

Multiple sclerosis (SM) is a chronic inflammatory and degenerative disease of the central nervous system. Its etiology has not been fully elucidated. For approximately 20 years, drugs have been used, successfully modifying the natural course of relapsing-remitting SM. One of them is interferon beta. Research outcomes of 16- and 21-year-retrospective follow-up of patients who participated in the pivotal interferon beta-1b trial were reported in 2010 and 2012, respectively. After 21 years, mortality rate among patients treated in the first 5 years with interferon beta-1b at a dose of 250μg was significantly lower, irrespective of the cause, as compared to the placebo-controlled group. Interferon beta-1b administered during the first 5 years of the study decreased the risk of death by 46.8% as compared to the placebo patients. Moreover, the studies also confirmed safety of long-term interferon beta-1b therapy. However, not much is known about the effect of interferon beta-1a on patients’ survival – the available data are presented in the article.

Abstract

Multiple sclerosis (SM) is a chronic inflammatory and degenerative disease of the central nervous system. Its etiology has not been fully elucidated. For approximately 20 years, drugs have been used, successfully modifying the natural course of relapsing-remitting SM. One of them is interferon beta. Research outcomes of 16- and 21-year-retrospective follow-up of patients who participated in the pivotal interferon beta-1b trial were reported in 2010 and 2012, respectively. After 21 years, mortality rate among patients treated in the first 5 years with interferon beta-1b at a dose of 250μg was significantly lower, irrespective of the cause, as compared to the placebo-controlled group. Interferon beta-1b administered during the first 5 years of the study decreased the risk of death by 46.8% as compared to the placebo patients. Moreover, the studies also confirmed safety of long-term interferon beta-1b therapy. However, not much is known about the effect of interferon beta-1a on patients’ survival – the available data are presented in the article.

Get Citation

Keywords

Multiple sclerosis, Mortality, Immodulatory treatment, Interferon beta

About this article
Title

Does interferon beta therapy affect survival of multiple sclerosis patients?

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 48, No 6 (2014)

Pages

436-441

DOI

10.1016/j.pjnns.2014.10.003

Bibliographic record

Neurol Neurochir Pol 2014;48(6):436-441.

Keywords

Multiple sclerosis
Mortality
Immodulatory treatment
Interferon beta

Authors

Alina Kułakowska
Wiesław Drozdowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl